atorvastatin, Lipitor
ApprovedSmall molecule
atorvastatin, Lipitor is one of 169 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
5
Indications
11
Total Trials
1
Active Trials
168
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
274 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1atorvastatin, Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Byetta
AstraZenecaPhase 3
Evacetrapib
Eli LillyPhase 3
AZD0780
AstraZenecaPhase 3
Repatha
AmgenPreclinical
Sibutramine Hydrochloride
AAbbott
Phase 3
Mounjaro
Eli LillyPreclinical
Praluent
RegeneronPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Myrbetriq
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atorvastatin3 trials
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00442845·2,080 enrolled
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00442325·595 enrolled
Clinical Trial1 trial
Toxicity1 trial
Efficacy1 trial
Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba
Completed·—·Phase 4·NCT00926614·20 enrolled
4 more indications
Efficacy and Safety1 trial
Hypercholesterolemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for atorvastatin, Lipitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details